Handok Teva announces co-promotion agreement of ‘Azilect’ with Lundbeck Korea

Published: 2015-12-03 14:52:46

Updated: 2015-12-03 14:52:46

Handok Teva(CEO Sun-dong Park) signed a co-promotion agreement of ‘Azilect,’ a Parkinson’s disease treatment, with Lundbeck Korea at the Lundbeck Korea headquarters in Seoul on the 30^th of December.

Under the term of the agreement, the two companies are planning to have 50:50 sales and marketing activities. The joint promotion agreement was conducted based on a business model that was successf...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Handok Teva announces co-promotion agreement of ‘Azilect’ with Lundbeck Korea

Handok Teva(CEO Sun-dong Park) signed a co-promotion agreement of ‘Azilect,’ a Parkinson’s disease treatment, with Lundbeck Korea at the Lundbeck Korea headquarters in Seoul on the 30th of December.

Fees

Handok Teva(CEO Sun-dong Park) signed a co-promotion agreement of ‘Azilect,’ a Parkinson’s disease treatment, with Lundbeck Korea at the Lundbeck Korea headquarters in Seoul on the 30^th of December.